TME Pharma Announces Successful Next Step in Its NOX-E36 Ophthalmology Strategy With Signature of Option Framework Agreement With Singapore Eye Research Institute (SERI)

The agreement establishes a strategic collaboration framework for NOX-E36, with TME Pharma securing an exclusive two-year option to out-license all rights related to NOX-E36 to either a newly created company or a third-party licensee. The framework reflects TME Pharma’s foundational investment and ownership of the underlying asset, while duly recognizing SERI’s pivotal contributions in early-stage ophthalmic research. Taking these respective contributions into account, the parties agreed to a fixed revenue-sharing model, with TME Pharma receiving a larger share of future licensing consideration. TME Pharma will lead the commercial discussions, streamlining engagement with potential investors and licensing partners interested in advancing NOX-E36's development in ophthalmology.

Through this collaboration, TME Pharma and SERI aim to progress NOX-E36 from preclinical research into clinical studies, leveraging their combined expertise to accelerate development. The near-term financial commitments include TME Pharma funding preclinical local ocular tolerance studies, while SERI will seek grants to fund and conduct the Phase 1b clinical study. Moreover, SERI will provide its deep expertise in ophthalmology research, pharmacological testing in animal models, and clinical evaluation, while TME Pharma will bring its prior clinical, regulatory and manufacturing experience and documentation as well as drug supply for both preclinical and clinical studies and will manage new intellectual property (IP).

Diskutieren Sie über die enthaltenen Werte

Noxxon Pharma N.V.

TME Pharma -0,98 % Aktie

4 Aufrufe heute

dr1mabuse 04.12.24, 21:09